Traditional antibody-drug conjugates (ADCs) have delivered cytotoxic payloads—often tubulin or topoisomerase inhibitors—directly to antigen-positive tumor cells, providing targeted cell killing while limiting off-target effects. However, the emergence of degrader–antibody conjugates (DACs), particularly those based on proteolysis-targeting chimeras (PROTACs) and molecular glues, has introduced a new therapeutic strategy: harnessing targeted protein degradation rather than inhibition. [1][2][3][4] This approach holds significant potential to expand the druggable proteome, overcome resistance, and improve the therapeutic index in oncology and beyond. [5][6]
Protein degradation is now recognized as a cornerstone of innovative therapeutic approaches for diseases characterized by the accumulation of aberrant or malfunctioning proteins. [1] While small-molecule inhibitors have long been used to block protein activity, they often fail to eliminate pathological proteins entirely and are limited by poor selectivity and off-target effects. [5][7] PROTACs and molecular glues offer catalytic protein elimination, recapitulating the effects of genetic knockout and providing prolonged pharmacodynamic effects [2][3][8]. However, these strategies face challenges with bioavailability, tissue penetration, and systemic toxicity. [3][6][9] By overcoming these limitations through antibody conjugation and advanced delivery mechanisms, DACs combine the tissue specificity of monoclonal antibodies with the catalytic efficiency of degraders, expanding the scope of previously ‘undruggable’ proteins. [4][8][10]
From ADCs to DACs
DACs are novel biotherapeutics that conjugate a protein degrader—such as a PROTAC or molecular glue—conjugated to a monoclonal antibody via a cleavable linker. [8][9][16] But DACs are not just ADCs with a novel payload—they offer a fundamentally different mechanism of action. While an antibody-drug conjugate (ADC) uses a targeted antibody attached to a cytotoxic payload, degrader-antibody conjugates replace the toxic payload with a targeted protein degrader. Rather than just inhibiting a targeted protein, the degrader-conjugate uses the cell’s own natural recycling machinery, the ubiquitin-proteasome system, to completely destroy the disease-driving protein. Because the degrader-conjugate can destroy multiple proteins sequentially, it requires much less drug to be effective, minimizing off-target toxicity.
Upon binding to antigen-expressing tumor cells, the conjugate is internalized, releasing the degrader payload to induce ubiquitin-dependent proteasomal degradation of selected target proteins. [2][11] This mechanism enables the removal of oncogenic drivers otherwise considered ‘undruggable’ and provides modularity for rational design and optimization. [8][12][13]
The versatility of PROTACs and molecular glues is reflected in their ability to recruit various E3 ligases (e.g., VHL, CRBN, and noncanonical ligases), enabling the degradation of multiple protein targets. [2][12]. Recent advances include the development of bifunctional and bispecific DACs, improved linker chemistries (e.g., pH-sensitive, enzyme-responsive, redox-sensitive), and the integration of advanced antibody engineering and computational modeling for optimized target engagement. [16][17][18][19][21] These innovations have enhanced pharmacokinetics, tissue specificity, and functional performance, while minimizing systemic and off-target effects [17][18][19][23].
Potential Beyond Oncology
While most DAC development has focused on oncology, the scope of targeted protein degradation technology extends to viral infections (HIV, COVID-19), neurodegenerative diseases (Alzheimer’s, Huntington’s, Parkinson’s), and chronic inflammatory disorders (atherosclerosis, atopic dermatitis). [9][24][25][26][37][38][39][40] DACs can be tailored to cell- and tissue-specificity, offering advantages in selectivity and safety. [10][13] New generations of PROTACs—such as TF-PROTACs, PhosphoTACs, and peptide-based conjugates—demonstrate enhanced pharmacokinetic stability, improved cellular permeability, and broader therapeutic applicability. [4][11][25]
The modularity of DACs enables rapid adaptation to emerging therapeutic targets, including those implicated in neurodegeneration and autoimmune diseases [10][13][38][39][40]. Their ability to degrade intracellular protein aggregates offers new possibilities for diseases previously refractory to small-molecule or antibody-based interventions. [24][39]
Safety Paradigms
Unlike cytotoxic ADCs, where collateral cell death is the principal concern, DACs introduce distinct safety challenges related to targeted protein degradation [8][16][26]:
- On-target/off-tumor degradation: Low-level antigen expression in normal tissues can deliver active degraders to healthy cells, risking depletion of essential proteins. [8][16]
- Off-target degradation: PROTACs and molecular glues may degrade unintended proteins, necessitating comprehensive, unbiased proteomic profiling to predict and monitor adverse effects. [8][9][12]
- Free degrader exposure: Premature linker cleavage or systemic catabolism may release active degrader into circulation, causing antigen-independent toxicity. [8][19]
- Bone marrow and gastrointestinal toxicity: Particularly relevant for molecular glues targeting essential proteins (e.g., GSPT1, IKZF-family, CK1α), where depletion in proliferative tissues can drive dose-limiting toxicities. [8][26]
- FcγR-mediated immune-cell uptake: Macrophages, monocytes, Kupffer cells, and dendritic cells may internalize DACs via Fcγ receptors, inadvertently exposing immune cells to the degrader [8].
- Species-translation uncertainty: Differences in E3 ligase expression, neosubstrate profiles, and degradation selectivity complicate extrapolation from animal toxicology to humans. [8][12]
Additional challenges for PROTAC-ADCs include payload size, hydrophobicity, lysosomal escape, ternary-complex formation, and potential “hook effects” at high concentrations. [6][12]. Linker chemistry and site-specific conjugation are crucial for ensuring stability in circulation and for selective release at the target site. [17][18][19]
Comparative Context: DACs, PROTACs, and Small-Molecule Inhibitors
DACs offer superior selectivity, stability, and tissue specificity compared to small-molecule inhibitors and traditional PROTACs [8,16]. Key comparative features are summarized below [Table 1][8][16]:
| Feature | Small-Molecule Inhibitors | PROTACs | Degrader–Antibody Conjugates (DACs) |
|---|---|---|---|
| Mechanism | Blocks the active site | E3 ligase-mediated | Antibody-targeted degradation |
| Selectivity | Moderate | High | Very high (antibody-guided) |
| Cell penetration | Passive/active transport | Limited | Antibody-mediated delivery |
| Stability | Rapid metabolism | Moderate | High (antibody provides stability) |
| Tissue specificity | Limited | Limited | High (antibody-guided) |
| Applications | Cancer, inflammation | Oncology, neurodegeneration | Oncology, neurodegeneration, autoimmune |
| Challenges | Off-targets, resistance | Bioavailability, hook effect | Complex production, immunogenicity |
Recent Advances in Degrader–Antibody Conjugates (DAC) Technology
Linker Chemistry
Innovation in cleavable linker design—including pH-sensitive, enzyme-responsive, and redox-sensitive linkers—has improved the stability and therapeutic precision of DACs. [17][18][19] Multifunctional linkers further expand DAC utility across diverse disease environments.
Target Engagement and Design
Computational modeling, machine learning, and advanced structural biology methods have enabled the rational design of high-affinity antibodies and optimized degrader moieties [20–22]. These efforts have generated new generations of DACs capable of targeting a broader spectrum of disease-associated proteins. [8][21][22]
Delivery Platforms
Enhanced tissue-specific and intracellular delivery has been achieved through bispecific and single-domain antibodies, nanoparticle encapsulation, and cell-penetrating peptides (CPPs). [23][24][25] Stimuli-responsive carriers allow for conditional and spatiotemporal modulation of target protein degradation. [4][24]
Dual-Targeting and Beyond
Dual-targeting DACs, which simultaneously engage two molecular targets or pathways, hold promise for synergistic efficacy, resistance overcoming, and reduced need for combination therapies. [27][28][29][30] Such strategies are being explored in oncology, autoimmune, and neurodegenerative disease models. [28][29][30]
Clinical Translation and Key Considerations
The successful clinical development of DACs requires more than achieving ADC-like exposure and tumor targeting. The critical biomarker for DACs is the demonstration of controlled, selective, tumor-restricted protein degradation. [8][16] Rational design—including antibody selection, linker chemistry, and degrader optimization—robust target validation, and comprehensive preclinical safety assessment (with unbiased proteomics) are essential. [8][16][17][18]
Comparative studies with other targeted protein degraders, such as LYTACs and AUTOTACs, are crucial for contextualizing DACs within the broader field of targeted protein degradation. [7] Advances in antibody and ligase engineering provide additional layers of tissue selectivity and safety. [10][15]
Perspective
DACs represent a transformative advance in targeted therapy, with the potential to expand the druggable proteome and overcome resistance mechanisms across oncology, neurodegeneration, and autoimmune disease. [8][13][24][26][38][39][40] While the clinical promise is substantial, the unique safety challenges posed by selective protein degradation demand a new paradigm in preclinical evaluation and patient monitoring. [8][16][26]
The future of DACs will depend on innovative solutions to these safety challenges and the continued integration of mechanistic insights, technological advances, and clinical rigor. Continued collaboration across academia, industry, and regulatory communities will be vital to realizing the full potential of DACs as next-generation therapeutics.
References:
[1] Chirnomas D, Hornberger KR, Crews CM. Protein degraders enter the clinic – a new approach to cancer therapy. Nat Rev Clin Oncol. 2023 Apr;20(4):265-278. doi: 10.1038/s41571-023-00736-3. Epub 2023 Feb 13. PMID: 36781982; PMCID: PMC11698446.
[2] Békés M, Langley DR, Crews CM. PROTAC targeted protein degraders: the past is prologue. Nat Rev Drug Discov. 2022 Mar;21(3):181-200. doi: 10.1038/s41573-021-00371-6. Epub 2022 Jan 18. PMID: 35042991; PMCID: PMC8765495.
[3] Martín-Acosta P, Xiao X. PROTACs to address the challenges facing small molecule inhibitors. Eur J Med Chem. 2021 Jan 15;210:112993. doi: 10.1016/j.ejmech.2020.112993. Epub 2020 Nov 5. PMID: 33189436; PMCID: PMC7779748.
[4] Lv MY, Hou DY, Liu SW, Cheng DB, Wang H. Strategy and Design of In Situ Activated Protein Hydrolysis Targeted Chimeras. ACS Nano. 2025 Jan 14;19(1):101-119. doi: 10.1021/acsnano.4c11903. Epub 2024 Dec 28. PMID: 39731609.
[5] Samarasinghe KTG, Crews CM. Targeted protein degradation: A promise for undruggable proteins. Cell Chem Biol. 2021 Jul 15;28(7):934-951. doi: 10.1016/j.chembiol.2021.04.011. Epub 2021 May 17. PMID: 34004187; PMCID: PMC8286327.
[6] Shen F, Dassama LMK. Opportunities and challenges of protein-based targeted protein degradation. Chem Sci. 2023 Jul 3;14(32):8433-8447. doi: 10.1039/d3sc02361c. PMID: 37592990; PMCID: PMC10430753.
[7] Lu H, Zhou Q, He J, Jiang Z, Peng C, Tong R, Shi J. Recent advances in the development of protein-protein interactions modulators: mechanisms and clinical trials. Signal Transduct Target Ther. 2020 Sep 23;5(1):213. doi: 10.1038/s41392-020-00315-3. PMID: 32968059; PMCID: PMC7511340.
[8] Dragovich PS. Degrader-antibody conjugates. Chem Soc Rev. 2022 May 23;51(10):3886-3897. doi: 10.1039/d2cs00141a. PMID: 35506708.
[9] Huang X, Wu F, Ye J, Wang L, Wang X, Li X, He G. Expanding the horizons of targeted protein degradation: A non-small molecule perspective. Acta Pharm Sin B. 2024 Jun;14(6):2402-2427. doi: 10.1016/j.apsb.2024.01.010. Epub 2024 Jan 20. PMID: 38828146; PMCID: PMC11143490.
[10] Gu Y, Wang Z, Wang Y. Bispecific antibody drug conjugates: Making 1+1>2. Acta Pharm Sin B. 2024 May;14(5):1965-1986. doi: 10.1016/j.apsb.2024.01.009. Epub 2024 Jan 20. PMID: 38799638; PMCID: PMC11119582.
[11] Cheng B, Li H, Peng X, Chen J, Shao C, Kong Z. Recent advances in developing targeted protein degraders. Eur J Med Chem. 2025 Feb 15;284:117212. doi: 10.1016/j.ejmech.2024.117212. Epub 2024 Dec 27. PMID: 39736199.
[12] Sobierajski T, Małolepsza J, Pichlak M, Gendaszewska-Darmach E, Błażewska KM. The impact of E3 ligase choice on PROTAC effectiveness in protein kinase degradation. Drug Discov Today. 2024 Jul;29(7):104032. doi: 10.1016/j.drudis.2024.104032. Epub 2024 May 22. PMID: 38789027.
[13] Van Regenmortel MH. Specificity, polyspecificity, and heterospecificity of antibody-antigen recognition. J Mol Recognit. 2014 Nov;27(11):627-39. doi: 10.1002/jmr.2394. PMID: 25277087.
[14] Sormanni P, Aprile FA, Vendruscolo M. Rational design of antibodies targeting specific epitopes within intrinsically disordered proteins. Proc Natl Acad Sci U S A. 2015 Aug 11;112(32):9902-7. doi: 10.1073/pnas.1422401112. Epub 2015 Jul 27. PMID: 26216991; PMCID: PMC4538631.
[15] Rojas G. Understanding and Modulating Antibody Fine Specificity: Lessons from Combinatorial Biology. Antibodies (Basel). 2022 Jul 14;11(3):48. doi: 10.3390/antib11030048. PMID: 35892708; PMCID: PMC9326607.
[16] Guo Y, Li X, Xie Y, Wang Y. What influences the activity of Degrader-Antibody conjugates (DACs). Eur J Med Chem. 2024 Mar 15;268:116216. doi: 10.1016/j.ejmech.2024.116216. Epub 2024 Feb 3. PMID: 38387330.
[17] Su Z, Xiao D, Xie F, Liu L, Wang Y, Fan S, Zhou X, Li S. Antibody-drug conjugates: Recent advances in linker chemistry. Acta Pharm Sin B. 2021 Dec;11(12):3889-3907. doi: 10.1016/j.apsb.2021.03.042. Epub 2021 Apr 6. PMID: 35024314; PMCID: PMC8727783.
[18] Deng S, Wen X, Wang J. Recent Advances in the Linkers of Drug Conjugates. Curr Med Chem. 2025;32(41):9367-9386. doi: 10.2174/0109298673320170240829110110. PMID: 39289930.
[19] Kern JC, Cancilla M, Dooney D, Kwasnjuk K, Zhang R, Beaumont M, Figueroa I, Hsieh S, Liang L, Tomazela D, Zhang J, Brandish PE, Palmieri A, Stivers P, Cheng M, Feng G, Geda P, Shah S, Beck A, Bresson D, Firdos J, Gately D, Knudsen N, Manibusan A, Schultz PG, Sun Y, Garbaccio RM. Discovery of Pyrophosphate Diesters as Tunable, Soluble, and Bioorthogonal Linkers for Site-Specific Antibody-Drug Conjugates. J Am Chem Soc. 2016 Feb 3;138(4):1430-45. doi: 10.1021/jacs.5b12547. Epub 2016 Jan 25. PMID: 26745435.
[20] Hummer AM, Abanades B, Deane CM. Advances in computational structure-based antibody design. Curr Opin Struct Biol. 2022 Jun;74:102379. doi: 10.1016/j.sbi.2022.102379. Epub 2022 Apr 28. PMID: 35490649.
[21] Zheng J, Wang Y, Liang Q, Cui L, Wang L. The Application of Machine Learning on Antibody Discovery and Optimization. Molecules. 2024 Dec 16;29(24):5923. doi: 10.3390/molecules29245923. PMID: 39770013; PMCID: PMC11679646.
[22] Wark KL, Hudson PJ. Latest technologies for the enhancement of antibody affinity. Adv Drug Deliv Rev. 2006 Aug 7;58(5-6):657-70. doi: 10.1016/j.addr.2006.01.025. Epub 2006 May 22. PMID: 16828920.
[23] Nessler I, Rubahamya B, Kopp A, Hofsess S, Cardillo TM, Sathyanarayan N, Donnell J, Govindan SV, Thurber GM. Improving Intracellular Delivery of an Antibody-Drug Conjugate Targeting Carcinoembryonic Antigen Increases Efficacy at Clinically Relevant Doses In Vivo. Mol Cancer Ther. 2024 Mar 4;23(3):343-353. doi: 10.1158/1535-7163.MCT-23-0437. PMID: 37913500; PMCID: PMC10932886.
[24] Rabbitts TH. Intracellular Antibodies for Drug Discovery and as Drugs of the Future. Antibodies (Basel). 2023 Mar 16;12(1):24. doi: 10.3390/antib12010024. PMID: 36975371; PMCID: PMC10044824.
[25] Ma J, Wehrle J, Frank D, Lorenzen L, Popp C, Driever W, Grosse R, Jessen HJ. Intracellular delivery and deep tissue penetration of nucleoside triphosphates using photocleavable covalently bound dendritic polycations. Chem Sci. 2024 Apr 2;15(17):6478-6487. doi: 10.1039/d3sc05669d. PMID: 38699261; PMCID: PMC11062083.
[26] Polakis P. Antibody Drug Conjugates for Cancer Therapy. Pharmacol Rev. 2016 Jan;68(1):3-19. doi: 10.1124/pr.114.009373. PMID: 26589413.
[27] Kontermann RE. Dual targeting strategies with bispecific antibodies. MAbs. 2012 Mar-Apr;4(2):182-97. doi: 10.4161/mabs.4.2.19000. Epub 2012 Mar 1. PMID: 22453100; PMCID: PMC3361654.
[28] Li JH, Liu L, Zhao XH. Precision targeting in oncology: The future of conjugated drugs. Biomed Pharmacother. 2024 Aug;177:117106. doi: 10.1016/j.biopha.2024.117106. Epub 2024 Jul 15. PMID: 39013223.
[29] Mihaylova R, Momekova D, Elincheva V, Momekov G. Immunoconjugates as an Efficient Platform for Drug Delivery: A Resurgence of Natural Products in Targeted Antitumor Therapy. Pharmaceuticals (Basel). 2024 Dec 17;17(12):1701. doi: 10.3390/ph17121701. PMID: 39770542; PMCID: PMC11677665.
[30] Taghipour YD, Zarebkohan A, Salehi R, Rahimi F, Torchilin VP, Hamblin MR, Seifalian A. An update on dual targeting strategy for cancer treatment. J Control Release. 2022 Sep;349:67-96. doi: 10.1016/j.jconrel.2022.06.044. Epub 2022 Jul 6. PMID: 35779656.
[31] Dastgheib ZS, Abolmaali SS, Farahavar G, Salmanpour M, Tamaddon AM. Gold nanostructures in melanoma: Advances in treatment, diagnosis, and theranostic applications. Heliyon. 2024 Aug 2;10(15):e35655. doi: 10.1016/j.heliyon.2024.e35655. PMID: 39170173; PMCID: PMC11336847.
[32] Zhou XL, Zhao F, Xu YT, Guan YY, Yu T, Zhang YZ, Duan YC, Zhao Y. A comprehensive review of BET-targeting PROTACs for cancer therapy. Bioorg Med Chem. 2022 Nov 1;73:117033. doi: 10.1016/j.bmc.2022.117033. Epub 2022 Sep 29. PMID: 36202064.
[33] Peters C, Brown S. Antibody-drug conjugates as novel anti-cancer chemotherapeutics. Biosci Rep. 2015 Jun 12;35(4):e00225. doi: 10.1042/BSR20150089. PMID: 26182432; PMCID: PMC4613712.
[34] Liu B, Zhou H, Tan L, Siu KTH, Guan XY. Exploring treatment options in cancer: Tumor treatment strategies. Signal Transduct Target Ther. 2024 Jul 17;9(1):175. doi: 10.1038/s41392-024-01856-7. PMID: 39013849; PMCID: PMC11252281.
[35] Chehelgerdi M, Chehelgerdi M, Allela OQB, Pecho RDC, Jayasankar N, Rao DP, Thamaraikani T, Vasanthan M, Viktor P, Lakshmaiya N, Saadh MJ, Amajd A, Abo-Zaid MA, Castillo-Acobo RY, Ismail AH, Amin AH, Akhavan-Sigari R. Progressing nanotechnology to improve targeted cancer treatment: overcoming hurdles in its clinical implementation. Mol Cancer. 2023 Oct 9;22(1):169. doi: 10.1186/s12943-023-01865-0. PMID: 37814270; PMCID: PMC10561438.
[36] Bahreyni A, Mohamud Y, Luo H. Oncolytic virus-based combination therapy in breast cancer. Cancer Lett. 2024 Mar 31;585:216634. doi: 10.1016/j.canlet.2024.216634. Epub 2024 Feb 1. PMID: 38309616.
[37] Tong H, Yang T, Xu S, Li X, Liu L, Zhou G, Yang S, Yin S, Li XJ, Li S. Huntington’s Disease: Complex Pathogenesis and Therapeutic Strategies. Int J Mol Sci. 2024 Mar 29;25(7):3845. doi: 10.3390/ijms25073845. PMID: 38612657; PMCID: PMC11011923.
[38] Ross CA, Poirier MA. Protein aggregation and neurodegenerative disease. Nat Med. 2004 Jul;10 Suppl:S10-7. doi: 10.1038/nm1066. PMID: 15272267.
[39] Lee SJ, Lim HS, Masliah E, Lee HJ. Protein aggregate spreading in neurodegenerative diseases: problems and perspectives. Neurosci Res. 2011 Aug;70(4):339-48. doi: 10.1016/j.neures.2011.05.008. Epub 2011 May 20. PMID: 21624403; PMCID: PMC3912578.
[40] Koszła O, Sołek P. Misfolding and aggregation in neurodegenerative diseases: protein quality control machinery as potential therapeutic clearance pathways. Cell Commun Signal. 2024 Aug 30;22(1):421. doi: 10.1186/s12964-024-01791-8. PMID: 39215343; PMCID: PMC11365204.
Note: This article is part of a series: The Magic Bullet, Realized – Antibody-drug Conjugates in Modern Oncology
Featured image: © 2022 Unsplash. Used with permission.
DOI
